SCHEMBL6073527

SCHEMBL6073527

CC(=O)Nc1cccc2c(S(=O)(=O)O)cccc12

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 1/20 0.60
EDNRA P25101 1/20 0.54
KMT2A Q03164 2/20 0.51
TTR P02766 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 1/20 0.49
CYP1A2 P05177 1/20 0.46
MAOA P21397 1/20 0.44
SLC40A1 Q9NP59 1/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1857055 0.90 KMT2A (0.59) CASP6EDNRAKMT2ATTRRXFP1
Hydrochloric Acid SCHEMBL8861874 0.89 KMT2A (0.57) CASP6EDNRAKMT2ARXFP1MEN1
SCHEMBL4115318 0.89 KMT2A (0.57) CASP6EDNRAKMT2ATTRRXFP1
SCHEMBL15461567 0.87 EDNRA (0.54) CASP6EDNRAKMT2ARXFP1MEN1
SCHEMBL10902168 0.86 TTR (0.53) CASP6KMT2ATTRMEN1KDM4E
SCHEMBL12994192 0.85 TTR (0.49) CASP6EDNRAKMT2ATTRALDH1A1
SCHEMBL3529089 0.85 EDNRA (0.53) CASP6EDNRAKMT2ARXFP1MEN1
SCHEMBL11441738 0.84 ALDH1A1 (0.47) CASP6EDNRATTRALDH1A1MAPT
Hydrochloric Acid SCHEMBL8054311 0.84 CDK2 (0.53) CASP6EDNRAKMT2ARXFP1MEN1
SCHEMBL21878720 0.84 EDNRA (0.52) CASP6EDNRAKMT2ARXFP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471363-A1 Use of aryl-, heteroaryl- and benzylsulfonamide carboxylic acids, -carboxylic acid esters, -carboxylic acid amides and -carbonitriles and/or its salts for increasing stress tolerance in plants Bayer CropScience AG (DE) 2012-07-04 EP disclosed
US-7026475-B2 Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-04-11 US disclosed
US-20040122003-A1 Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-06-24 US disclosed
US-20040116412-A1 Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-06-17 US disclosed
EP-1404340-A1 NAPHTOTHIAZINE POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS (PAARM) Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-04-07 EP disclosed
US-20030100552-A1 Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-05-29 US disclosed
WO-2002100411-A1 NAPHTOTHIAZINE POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS (PAARM) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-12-19 WO disclosed
EP-0558258-B1 N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists SQUIBB & SONS INC (US) 1997-05-07 EP disclosed
US-5378715-A Sulfonamide endothelin antagonists BRISTOL-MYERS SQUIBB CO. (US) 1995-01-03 US disclosed
EP-0558258-A1 N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists E.R. SQUIBB & SONS, INC. (US) 1993-09-01 EP disclosed
US-4749523-A NEUTRALIZING ACID AND SUBSEQUENT AMINE ACYLATION TO AMIDE GROUP; EFFICIENT HOECHST CELANESE CORPORATION (US) 1988-06-07 US disclosed
EP-0168680-B1 SOLID PHASE ACYLATION OF AMINOSULFONIC ACIDS HOECHST CELANESE CORPORATION (US) 1988-03-09 EP disclosed
EP-0168680-A1 Solid phase acylation of aminosulfonic acids HOECHST CELANESE CORPORATION (US) 1986-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100552-A1 Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions GRM1, GRM2, GRIN1 CASP6 4875/4885EDNRA 389/4885KMT2A 1246/4885
US-20040122003-A1 Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions GRM1, GRM2, GRIN1 CASP6 4875/4885EDNRA 389/4885KMT2A 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.